Personalis Study Highlights Ultrasensitive ctDNA Testing for Breast Cancer Prognosis
Event summary
- Personalis published the PREDICT-DNA study in the Journal of Clinical Oncology, demonstrating the utility of its NeXT Personal assay for monitoring breast cancer treatment response.
- The study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across 24 US cancer centers.
- The study found that 55% of detectable ctDNA post-neoadjuvant therapy occurred below 100 parts per million, highlighting the importance of ultrasensitive testing.
- ctDNA status post-neoadjuvant therapy was a stronger predictor of recurrence than traditional metrics like nodal status and pathologic complete response (pCR).
The big picture
The PREDICT-DNA study validates the growing trend towards personalized oncology and the use of liquid biopsies for treatment monitoring. The ability to detect minimal residual disease (MRD) with greater sensitivity offers the potential to improve patient outcomes and guide treatment decisions, but also introduces challenges related to cost, reimbursement, and clinical adoption. This finding could accelerate the shift away from traditional, less precise, diagnostic methods in oncology.
What we're watching
- Reimbursement
- The success of Personalis’ efforts to expand reimbursement coverage for NeXT Personal will be critical for widespread adoption and revenue growth, particularly given the assay’s higher cost relative to standard approaches.
- Clinical Adoption
- The pace at which oncology centers integrate ultrasensitive ctDNA testing into standard clinical workflows will determine the assay’s impact on patient outcomes and Personalis’ market penetration.
- Competitive Landscape
- How competitors respond to Personalis’ findings and develop competing ultrasensitive ctDNA assays will shape the long-term viability of the market and Personalis’ competitive advantage.
Related topics